Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. [electronic resource]
Producer: 20100304Description: 767-72 p. digitalISSN:- 1527-7755
- Administration, Oral
- Adult
- Aged
- Antineoplastic Agents -- administration & dosage
- Biomarkers, Tumor -- blood
- Calcitonin -- blood
- Carcinoembryonic Antigen -- blood
- Carcinoma, Medullary -- drug therapy
- Disease-Free Survival
- Drug Administration Schedule
- Female
- France
- Genetic Predisposition to Disease
- Germ-Line Mutation
- Humans
- Kaplan-Meier Estimate
- Male
- Middle Aged
- Pedigree
- Piperidines -- administration & dosage
- Protein Kinase Inhibitors -- administration & dosage
- Proto-Oncogene Mas
- Proto-Oncogene Proteins c-ret -- antagonists & inhibitors
- Quinazolines -- administration & dosage
- Risk Factors
- Thyroid Neoplasms -- drug therapy
- Time Factors
- Treatment Outcome
- United States
- Young Adult
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.